A detailed history of Greystone Financial Group, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Greystone Financial Group, LLC holds 1,117 shares of VRTX stock, worth $560,421. This represents 0.09% of its overall portfolio holdings.

Number of Shares
1,117
Previous 895 24.8%
Holding current value
$560,421
Previous $419,000 23.87%
% of portfolio
0.09%
Previous 0.08%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

BUY
$460.0 - $505.78 $102,120 - $112,283
222 Added 24.8%
1,117 $519,000
Q2 2024

Aug 06, 2024

BUY
$392.81 - $485.53 $351,564 - $434,549
895 New
895 $419,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Greystone Financial Group, LLC Portfolio

Follow Greystone Financial Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Greystone Financial Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Greystone Financial Group, LLC with notifications on news.